Alpha-1 Foundation Supports NIH Funding
Stand with rare diseases and support critical NIH funding
Below are the reasons this is important to Alpha-1 Patients.
Congress is currently considering proposals that would reduce the NIH budget by 40%. Such cuts would be devastating—slowing research progress and delaying critical advancements in the diagnosis and treatment of rare diseases like Alpha-1 Antitrypsin Deficiency (Alpha-1).
The Ad Hoc Group for Medical Research, which includes the Alpha-1 Foundation (A1F) and more than 530 organizations, recommends Congress provide no less than $51.3 billion for NIH in FY 2026, along with sustained support for the Advanced Research Projects Agency for Health (ARPA-H). This 9% increase is essential to continue the momentum of lifesaving biomedical research.
Why This Matters for Alpha-1 Patients and the Nation:
· NIH research has driven every major advance in Alpha-1 therapies.
· Funding cuts will delay progress on lung and liver disease treatments.
· NIH supports scientists, institutions, and innovation in every state—including right here in your district.
· Research investment generates jobs, stimulates local economies, and improves long-term
health outcomes. Please stand with patients, families, and communities affected by rare diseases. Oppose NIH budget cuts and ensure robust investment in medical research by supporting at least $51.3 billion in FY 2026 funding for the NIH.